Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

NCT03592264 is registered in ClinicalTrials.gov with OBI Pharma, Inc as lead sponsor.

NCT NCT03592264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03592264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Lead sponsor
OBI Pharma, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
July 2, 2018
Completion date
March 21, 2024
Enrollment
68 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, solid tumor